**Active IPO activity through late September 2026 underpins strong trader consensus that additional listings will occur before year-end.** Multiple offerings are scheduled to price and trade in the final days of Q3, including Oura Inc. (targeting a roughly $2.1 billion raise at $40–44 per share) and Accelevation Holdings Corp. (approximately $660 million at $20–24), alongside smaller biotech and SPAC-related deals. Year-to-date volume stands at 249 U.S. IPOs, only modestly below 2025’s pace, supported by resilient equity markets and sector-specific demand in AI infrastructure and healthcare. Recent pricings show selectivity, with some names posting gains and others declining, while larger candidates such as Anthropic remain on track for Q4 or have slipped. Key near-term catalysts include final pricing windows, economic data releases, and any shifts in Treasury yields or risk appetite that could influence issuer timing through December.